ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Attributes of HPV associated cancers.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Global burden and cross-country inequalities in head and neck cancer from 1992 to 2021: results from the global burden of disease study.Health economics review · 2025Article
- Article
- Assessment of human papillomavirus literacy among midwifery students: a cross-sectional study.Revista da Associacao Medica Brasileira (1992) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncogenic human papillomavirus (HPV) has been strongly implicated in the etiology of cervical cancer and its prevalence in patients with head and neck cancers, particularly oropharyngeal cancers (OPCs), is increasing at an alarming rate. In developed Western nations, HPV is responsible for approximately 90% of all OPC cases, while the proportion of HPV-related OPCs is progressively rising in developing countries. The 8th edition of the American Joint Committee on Cancer (AJCC) now incorporates HPV status as part of the staging system for oropharyngeal cancers. Moreover, due to distinct molecular pathways, the clinical presentation of HPV-positive tumors differs from that of HPV-negative tumors, a phenomenon supported by numerous studies. Despite these differences, the treatment regimens for HPV-associated cancers generally remain analogous to those for their HPV-negative counterparts. This review aims to elucidate the unique tumor characteristics and underlying molecular aberrations associated with HPV-induced malignancies.
Indexed as
Identifiers
40452000What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.